Developmental dynamics of homoarginine, ADMA and SDMA plasma levels from birth to adolescence
Standard
Developmental dynamics of homoarginine, ADMA and SDMA plasma levels from birth to adolescence. / Baach, Florence; Meyer, Boglarka; Oh, Jun; Lezius, Susanne; Böger, Rainer; Schwedhelm, Edzard; Choe, Chi-Un; Neu, Axel.
in: AMINO ACIDS, Jahrgang 55, Nr. 10, 10.2023, S. 1381-1388.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Developmental dynamics of homoarginine, ADMA and SDMA plasma levels from birth to adolescence
AU - Baach, Florence
AU - Meyer, Boglarka
AU - Oh, Jun
AU - Lezius, Susanne
AU - Böger, Rainer
AU - Schwedhelm, Edzard
AU - Choe, Chi-Un
AU - Neu, Axel
N1 - © 2023. The Author(s).
PY - 2023/10
Y1 - 2023/10
N2 - Guanidino compounds such as dimethylarginines (SDMA, ADMA) and L-homoarginine ((L-)hArg) can interfere with bioavailability and function of the main NO-donor L-arginine (L-Arg). High ADMA and SDMA but low L-hArg concentrations have been associated with cardio- and cerebrovascular events and mortality in adults. The role of guanidino compounds in paediatric patients remains less clear. We, therefore, compared guanidino compound levels in plasma samples of 57 individuals with chronic kidney disease (CKD) and 141 individuals without CKD from the age of 0 to 17 years, including patients with different comorbidities by correlation and regression analyses. We found highest hArg, SDMA and ADMA concentrations in neonates (Kruskal-Wallis, p < 0.001 for all). From the age of 1 year on, hArg levels increased, whereas SDMA und ADMA levels further decreased in children. SDMA and ADMA are higher in children with CKD independent of GFR (mean factor 1.92 and 1.38, respectively, p < 0.001 for both), and SDMA is strongly correlated with creatinine concentration in children with CKD (Spearman's rho 0.74, p < 0.001). We provide guanidino compound levels in a large sample covering all paediatric age groups for the first time. Our data can be used to assess the role of guanidino compounds such as hArg in disease states, i.e. cerebro- and cardiovascular disorders in childhood and adolescence.
AB - Guanidino compounds such as dimethylarginines (SDMA, ADMA) and L-homoarginine ((L-)hArg) can interfere with bioavailability and function of the main NO-donor L-arginine (L-Arg). High ADMA and SDMA but low L-hArg concentrations have been associated with cardio- and cerebrovascular events and mortality in adults. The role of guanidino compounds in paediatric patients remains less clear. We, therefore, compared guanidino compound levels in plasma samples of 57 individuals with chronic kidney disease (CKD) and 141 individuals without CKD from the age of 0 to 17 years, including patients with different comorbidities by correlation and regression analyses. We found highest hArg, SDMA and ADMA concentrations in neonates (Kruskal-Wallis, p < 0.001 for all). From the age of 1 year on, hArg levels increased, whereas SDMA und ADMA levels further decreased in children. SDMA and ADMA are higher in children with CKD independent of GFR (mean factor 1.92 and 1.38, respectively, p < 0.001 for both), and SDMA is strongly correlated with creatinine concentration in children with CKD (Spearman's rho 0.74, p < 0.001). We provide guanidino compound levels in a large sample covering all paediatric age groups for the first time. Our data can be used to assess the role of guanidino compounds such as hArg in disease states, i.e. cerebro- and cardiovascular disorders in childhood and adolescence.
U2 - 10.1007/s00726-023-03318-w
DO - 10.1007/s00726-023-03318-w
M3 - SCORING: Journal article
C2 - 37648945
VL - 55
SP - 1381
EP - 1388
JO - AMINO ACIDS
JF - AMINO ACIDS
SN - 0939-4451
IS - 10
ER -
